BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34693628)

  • 21. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A gene expression signature for relapse of primary wilms tumors.
    Li W; Kessler P; Yeger H; Alami J; Reeve AE; Heathcott R; Skeen J; Williams BR
    Cancer Res; 2005 Apr; 65(7):2592-601. PubMed ID: 15805255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
    J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gain of MYCN region in a Wilms tumor-derived xenotransplanted cell line.
    Noguera R; Villamón E; Berbegall A; Machado I; Giner F; Tadeo I; Navarro S; Llombart-Bosch A
    Diagn Mol Pathol; 2010 Mar; 19(1):33-9. PubMed ID: 20186010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study.
    Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC
    J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia.
    Schiavetti A; Varrasso G; Collini P; Clerico A
    J Pediatr Hematol Oncol; 2018 May; 40(4):331-333. PubMed ID: 28859044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases.
    Re GG; Hazen-Martin DJ; El Bahtimi R; Brownlee NA; Willingham MC; Garvin AJ
    Int J Cancer; 1999 Apr; 84(2):192-200. PubMed ID: 10096254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center.
    Zuppan CW; Beckwith JB; Luckey DW
    Hum Pathol; 1988 Oct; 19(10):1199-209. PubMed ID: 2844645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The epithelial mesenchymal transition process in wilms tumor: a study based on a xenograft model.
    Giner F; Machado I; Noguera R; Villamon E; Pellin A; Calabuig-Fariñas S; Peydro-Olaya A; Navarro S; Llombart-Bosch A
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):369-75. PubMed ID: 21285869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaplastic Wilms' tumor: clinical and pathologic studies.
    Bonadio JF; Storer B; Norkool P; Farewell VT; Beckwith JB; D'Angio GJ
    J Clin Oncol; 1985 Apr; 3(4):513-20. PubMed ID: 2984344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro.
    Wegert J; Bausenwein S; Kneitz S; Roth S; Graf N; Geissinger E; Gessler M
    Mol Cancer; 2011 Nov; 10():136. PubMed ID: 22067876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
    Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
    Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors.
    Su X; Lu X; Bazai SK; Dainese L; Verschuur A; Dumont B; Mouawad R; Xu L; Cheng W; Yan F; Irtan S; Lindner V; Paillard C; Le Bouc Y; Coulomb A; Malouf GG
    Nat Commun; 2023 Nov; 14(1):7884. PubMed ID: 38036539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
    Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
    Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
    Rakheja D; Khokhar S; Mitui M; Cost NG
    Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.